UNSPSC 51422334: Dexamethasone acetate anhydrous

This classification denotes a therapeutic glucocorticoid and antiemetic agent with the molecular formula C24H31FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K7V8P532WP, chemically known as pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-fluoro-11,17-dihydroxy-16-methyl-, (11.beta.,16.alpha.)-, but more generally known as dexamethasone acetate anhydrous, which bears US NIH Compound Identifier 14442.

UNSPSC 51422334 Dexamethasone acetate anhydrous is a Commodity code nominally identifying a specific corticosteroid pharmaceutical product, but recent state and local opportunities tagged under this code show minimal alignment with its pharmaceutical scope. The two opportunities on record involve naloxone procurement and direct-to-manufacturer prescription program consulting—neither directly related to dexamethasone acetate anhydrous. This code shows little relevant recent activity for vendors focused on the stated active pharmaceutical ingredient.

Geographic activity appears limited to Florida and Texas based on current records. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with a July 26, 2023 response deadline; the Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program. Neither opportunity directly aligns with dexamethasone acetate anhydrous procurement, suggesting this code may be misapplied in the state and local taxonomy for these particular solicitations or that actual dexamethasone demand through public buyers remains unrecorded in available notices.